Antioxidant status in children with malignancies

Thesis

Submitted for partial fulfilment of Master Degree in Pediatrics

By

Hoda Ismail Abdel Razek Hassan MBBCH 2004 Faculty of Medicine-Ain Shams University

Under Supervision of

Prof. Dr. Sanaa Youssef Shaban

Professor of Pediatrics
Faculty of medicine-Ain Shams University

Prof. Dr. Galila Mohamed Mokhtar

Professor of Pediatrics
Faculty of medicine-Ain Shams University

Dr. Hala Abdel Al Ahmed

Lecturer of clinical and chemical pathology Faculty of medicine-Ain shams university

> Faculty of medicine Ain shams university 2010

مستوى مضادات الأكسدة لدى الأطفال المصابين بالأورام السرطانية

رسالة مقدمة من الطبيبة / هدى اسماعيل عبد الرازق حسن بكالوريس الطب والجراحه جامعة عين شمس

توطئه للحصول على درجة الماجستير في طب الاطفال

تحت اشراف أ.د/ سناء يوسف شعبان استاذ طب الاطفال كلية الطب – جامعة عين شمس

أ.د/ جليله محمد مختار استاذ طب الاطفال كلية الطب – جامعة عين شمس

د/هاله عبد العال احمد مدرس الباثولوجيه الاكلينيكيه والكيميائيه كلية الطب -جامعة عين شمس

كلية الطب جامعة عين شمس 2010

Acknowledgement

First and fore most thanks to allah the most beneficent and merciful

I wish to express my great appreciation to prof.Dr.sanaa Youssef shaban professor of pediatric- Ain shams university for her great support, guidance and encouragement.

I would like to express my deepest thanks and gratitude to prof. Dr.Galila Mohamed Mokhtar professor of pediatric- Ain shams university

Many thanks to Dr.hala Abdel Al Ahmad Lecturer of clinical and chemical pathology Faculty of Medicine Ain shams university.for her generous help, supervision and extreme kindness through out the work

Words are not enough to thank Dr. Nancy Samir Elbarbary, Lecturer of Pediatrics, Faculty of medicine, Ain shams university. Who gave me the honor of working under her supervision, for her careful and great support in this study.

I wish to express great appreciation and gratitude to all patients of this study and their parents whose cooperation was indispensable for completion of this work

Finally, I wish to express my great appreciation and gratitude to my father, mother, sister and brothers for their Support

> Hoda Ismail



Contents

Subjects	Page
List of Abbreviations	I
• List of Tables	II
• List of Figures	V
• Introduction	1
Aim of the Work	3
• Review of literature:	
- Chapter (1): Pediatric malignancies	4
- Chapter (2): Oxidative stress and antioxidants	31
- Chapter (3): Chemotherapy and antioxidants	55
Patients and Methods	62
• Results	74
• Discussion	110
Summery and Conclusion	127
Recommendations	131
• References	132
Arabic Summary	
• Appendix	

List Abbreviations

AFP : Alpha-fetoprotein

AGE : Advanced glycation end products

ALE : Advanced lipo-oxidation end products

ALL : Acute lymphoblastic leukemia

AML : acute myeloid leukemia

CAT : Catalase

CNS : Central nervouse system

COX : Cyclo-oxygenaseEBV : Epstein-Barr virus

FAP : familial adenomatous polyposis

GPX : Glutathione peroxidase

HIV : Human immuno deficiency virus

HL : Hodgkin lymphoma

HTLV: Human T-cell lympho tropic virus

LOX : Lipoxgenase

MDA : Malondialdhyde

NHL: Non-Hodgkin Lymphoma

PUFA : Poly unsaturated fatty acids

RNS : Reactive nitrogen species

ROS : Reactive oxygen species

SAMe : SAdenosyl-L-methionine

SOD : Superoxide dismutase

WBCs: White blood cells

List of Tables

Table No.	Title	Page
Table (1)	Location and distribution of rhabdomyosarcoma	28
Table (2)	Sources of vitamin C	43
Table(3)	The Daily Reference Intakes (DRI) for vitamin C	47
Table (4)	Representive antineoplastic agents mechanism of action and major toxicities	57
	Characteristics of enrolled patients with	74
Table (5)	hematological and solid tumors as regards anthropometric measurements	
Table (6)	Characteristics of enrolled patients with	76
	hematological and solid tumors as	
	regards mean values of hematological	
Table (7)	measurement Characteristics of annulled matients with	77
Table (7)	Characteristics of enrolled patients with hematological and solid tumors as	77
	regards range and mean values of	
	biochemical measurements	
Table (8)	Characteristics of enrolled patients with	78
	hematological and solid tumors as	
	regards range and mean values of	
	antioxidants ,oxidative marker(MDA)	
Table (9)	Comparison between hematological measurements during six months of chemotherapy treatment	79




Table No.	Title	Page
Table (10)	Comparison between hematological parameters during six months of chemotherapy treatment in patients with hematological malignancies	80
Table (11)	Comparison between hematological parameters during six months of chemotherapy treatment in patients with solid tumors	81
Table (12)	Comparison between biochemical measurements during six months of chemotherapy treatment	82
Table (13)	Comparison between biochemical parameters during six months of chemotherapy treatment in patients with hematological malignancies.	85
Table (14)	Comparison between mean levels of biochemical parameters during six months of chemotherapy treatment in patients with solid tumors	86
Table (15)	Classification of cases according to normal values of vitamin C, malondialdhyde &TAC	87
Table (16)	Comparison between mean values of antioxidants During six months of chemotherapy treatment	88
Table (17)	Comparison between mean levels of antioxidants during six months of chemotherapy treatment in patients with hematological malignancies	92





Table No.	Title	Page
Table (18)	Comparison between mean levels antioxidants during six months of chemotherapy treatment in patients with solid tumors	93
Table (19)	Comparison between patients with hematological malignancies and solid tumors as regards changes in VIT C, TAC and Malondialdehyde during six months of chemotherapy treatment	95
Table (20)	Comparison between patients with hematological malignancies and solid tumors as regards changes in VIT C, TAC and Malondialdehyde during six months of chemotherapy treatment	96
Table (21)	Comparison between adverse effects during six months of chemotherapy treatment	100
Table (22)	Correlation between mean values of VIT C, TAC and Malondialdehyde levels	105
Table (23)	Comparison between male and female patients as regards level of Vit C,TAC.MDA during six months of chemotherapy treatment	106
Table (24)	Comparison between mean values of Vit C,TAC,MDA as regards age of patients	107
Table (25)	Comparison between hematological and solid tumors as regards adverse effects	108
Table (26)	Comparison between level of TAC and adverse effects after six months of chemotherapy treatment	109



List of Figures

Fig. No.	Title	Page
Fig. (1)	Exogenous and endogenous sources of reactive oxygen species	32
Fig. (2)	Reactive oxygen species (ROS)-induced oxidative damage	38
Fig. (3)	Structure of ascorbic acid	42
Fig. (4)	Percentage of different types of malignancies of enrolled patients in the study.	75
Fig. (5)	Effect of six months chemotherapy on liver function tests	83
Fig. (6)	Effect of six months chemotherapy on kidney function test	84
Fig. (7)	Changes in mean values of Vitamin C levels during six months of chemotherapy treatment	90
Fig. (8)	Comparison between changes in mean values of Vitamin C and MDA during six months of chemotherapy treatment	91
Fig. (9)	Changes in the level of vitamin C during six months of chemotherapy	97
Fig. (10)	Changes in the level of TAC during six months of chemotherapy	98
Fig. (11)	Changes in mean levels of MDA during six months of chemotherapy	99
Fig. (12)	Incidence of dose reduction during six months of chemotherapy	101
Fig. (13)	Incidence of infection during three and six months of chemotherapy	102
Fig. (14)	Incidence of stoppage of chemotherapy after six months of chemotherapy	103
Fig. (15)	Incidence of hospitalization during six month of chemotherapy	104



Introduction

Acute leukemia is the most common form of childhood cancer and is the primary cause of cancer related mortality in children, the etiology of leukemia is poorly understood, and both genetic and environmental factors have been implicated.

A huge body of evidence from human and animal studies indicates altered metabolism in cancer (*Ziegler et al.*, 2005).

Antioxidants allow aerobic organisms to withstand daily episodes of oxidative stress by counteracting the adverse effect of free radicals, which are produced by metabolic activities within the body, the levels of antioxidants not only provide protection against oxidation but also reflect their consumption during acute oxidative stress. Whenever antioxidant capacity is outflanked by oxidative stress, tissue lesion may occur (*Pelicano et al.*, 2003).

Antioxidants constitute a highly heterogeneous group they include low molecular weight substances either water (e.g. ascorbic acid) or lipid-soluble (e.g vitamin E), incorporated in the body through nutrition. In addition a number of endogenous metabolites (uric acid, lipids, albumin, bilirubin) possess antioxidant activities (*Malliaraki et al.*, 2003).



The sum of endogenous and food- derived antioxidants represents the total antioxidant capacity (TAC) of extra cellular fluids, which can be assessed by various methods .TAC integrates the cumulative effect of all antioxidants present in the plasma and body fluids and may give more relevant biological information as compared to the obtained by the measurements of individual parameters (*Kampa et al.*, 2002).

In vitro and in vivo data suggest that certain antioxidants selectively inhibit the growth of tumor cells, may induce cellular differentiation, and may alter the intracellular state, thereby enhancing the effects of cytotoxic therapy (*Conklin, et al., 2002*).

Aim of the Study

The aim of the present study is to:

- i. Identify antioxidant status in children with malignancies.
- ii. Investigate the effect of conventional chemotherapy on antioxidant status.
- iii. Determine the effect of antioxidant status on treatment related toxicities.

Pediatric Malignancies

1- Acute Lymphoblastic Leukemia:

Epidemiology:

Acute leukemia, the most common form of cancer in children, comprises approximately 30 percent of all childhood malignancies, with acute lymphoblastic leukemia (ALL) being five times more common than acute myeloid leukemia (AML). Each year in the United States approximately 2500 to 3500 new cases of ALL are diagnosed in children. Survival rates for leukemia have improved dramatically since the 1980s, with a current five-year survival rate of approximately 78 percent. This improvement is in large part because of treatment of large numbers of children with sequential standardized research protocols. Approximately 75 to 80 percent of children with newly diagnosed ALL participate in clinical research trials, the goals of which are to improve clinical outcome and to minimize acute toxicities and late-occurring adverse events (*Greenlee et al.*, 2000).

As mentioned above, approximately 2500 to 3500 new cases of ALL are diagnosed in children each year in the United States with an incidence of 2.8 cases per 100,000. It appears the incidence of childhood leukemia is increasing as demonstrated by the two following studies: In a study that used data from 63

European population-based cancer registries of children diagnosed with cancer, the incidence of leukemia including ALL increased by an average of 1.4 percent from 1970 to 1999. In a study from Great Britain, the incidence of leukemia (mostly attributable to ALL) has steadily increased from 3.83 to 4.61 per 100,000 persons by sex and age from the five-year period of 19971 to 1975 and 1996 to 2000 (*Shah and Coleman*, 2007).

In contrast, a study from four Nordic countries (Denmark, Finland, Norway, and Sweden) reported that the incidence of childhood ALL remained stable at an approximate rate of 3.3 cases per 100,000 children below 15 years of age from 1983 to 2002 after an increase in incidence between 1975 and 1983. The peak incidence occurs between 2 and 5 years of age, and it occurs more commonly among boys than girls. In the United States, ALL occurs two times more commonly among white than black children (*Svendsen et al.*, 2007).

Diagnosis:

The diagnosis and classification of leukemia are based upon specialized tests that are performed on cells derived from a bone marrow aspirate or tissue biopsy specimens. When clinical circumstances preclude bone marrow examination, the diagnosis can be made from cells obtained from peripheral leukopheresis or pleural effusions. The diagnosis of CNS